Estrogen, Inflammation, and the Brain: What Menopause May Mean for Long-Term Brain Health
When we talk about estrogen, we often talk about reproductive health: menstrual cycles, fertility, hot flashes, and menopause.
But estrogen is also a brain hormone.
Estrogen receptors are found throughout the brain, including regions involved in memory, mood, sleep, emotional regulation, and cognition. Estrogen also interacts with the immune system, cardiovascular system, glucose metabolism, and the mitochondria that provide energy to our cells (Brinton et al., 2015).
That means the hormonal changes of perimenopause aren't occurring in isolation. They are part of a much broader biological transition.
Researchers are increasingly interested in what this transition may mean not only for how women feel during their 40s and 50s, but also for brain health decades later.
Estrogen Does Much More Than Regulate Reproduction
Estrogen—particularly estradiol—affects numerous processes within the brain.
It interacts with serotonin, dopamine, and other neurotransmitter systems involved in mood and motivation. It influences synaptic plasticity, which allows connections between neurons to change and adapt. It also affects cerebral blood flow, mitochondrial function, glucose metabolism, and immune signaling (Brinton et al., 2015).
Estrogen has important neuroprotective and immunomodulatory effects in many biological contexts. This helps explain why changing estrogen levels can potentially produce effects that seem unrelated to reproduction.
For some women, perimenopause brings anxiety, insomnia, irritability, depression, difficulty concentrating, or the familiar experience often described as "brain fog." Mood and cognitive changes across the menopausal transition have been documented in the literature, although experiences vary substantially between individuals (Maki et al., 2018; Weber et al., 2014).
These symptoms are real, but they also raise a larger question:
What is happening inside the brain as estrogen changes?
Estrogen and Inflammation
Inflammation isn't inherently harmful. It is an essential part of the body's immune response. The problem is persistent, dysregulated inflammation.
Estrogen helps modulate immune activity and inflammatory signaling throughout the body and influences immune activity within the central nervous system. As ovarian function changes during perimenopause and estrogen ultimately declines after menopause, some of these regulatory effects change as well.
However, the relationship is more complicated than simply saying that estrogen loss "causes inflammation." Other changes commonly occurring during midlife can contribute to a more pro-inflammatory environment, including increasing visceral fat, insulin resistance, disrupted sleep, chronic stress, and declining physical activity.
In other words, menopause affects multiple interconnected biological systems at the same time.
And one of the systems affected by those changes is the brain.
Why Does Inflammation Matter for Mental Health?
The immune system and the brain are in constant communication. Inflammatory signaling can affect neurotransmitter metabolism, neuroplasticity, the stress-response system, sleep, motivation, and neural circuits involved in mood.
Research has identified an association between inflammation and depression, particularly in subsets of individuals with elevated inflammatory activity. Inflammation has also been associated with symptoms such as fatigue, sleep disturbance, cognitive difficulties, and reduced motivation.
This does not mean that depression is simply an inflammatory disease—or that treating inflammation will cure depression. Psychiatric disorders arise from complex interactions among biology, psychology, genetics, environment, relationships, and life experiences. But inflammation can be one piece of that larger picture.
For a woman entering perimenopause, several changes may happen simultaneously:
Hormones fluctuate. Sleep becomes disrupted. Body composition changes. Insulin sensitivity may decline. Stress may become harder to tolerate. Inflammatory signaling may change.
Looking at only one of those factors can miss the way they interact.
The Brain Has Enormous Energy Requirements
Another fascinating area of menopause research involves brain metabolism. Although the brain represents only a small percentage of total body weight, it consumes a substantial proportion of the body's energy. Neurons require a continuous supply of energy to communicate, maintain connections, and perform the complex work underlying thought, memory, and emotion.
Estrogen helps regulate how the brain uses glucose and supports mitochondrial function. Researchers have therefore proposed that the menopausal transition represents not simply a reproductive transition, but a neurological and metabolic transition as well (Brinton et al., 2015).
Human neuroimaging research has identified changes in brain structure, connectivity, energy metabolism, and other biomarkers across the menopausal transition (Mosconi et al., 2021). This doesn't mean that the brain simply "runs out of fuel" when estrogen declines. Rather, the research suggests that menopause may involve a period of metabolic adaptation within the brain.
That connection becomes especially interesting when we consider another major component of midlife health: metabolism throughout the rest of the body.
Estrogen, Insulin Resistance, and Metabolic Health
The menopausal transition is often accompanied by changes in body composition, including a greater tendency toward central or visceral fat accumulation.
Visceral fat isn't simply passive energy storage. It is metabolically active tissue capable of producing inflammatory signals. Changes in estrogen signaling are also associated with changes in insulin sensitivity, lipid metabolism, vascular function, and cardiovascular risk.
These processes can interact:
Insulin resistance can promote inflammation.
Inflammation can interfere with insulin signaling.
Visceral adiposity can contribute to both.
This matters because metabolic health isn't separate from brain health. Diabetes, hypertension, cardiovascular disease, obesity, and physical inactivity are among the factors associated with increased risk of cognitive decline and dementia later in life.
For psychiatry, this relationship is particularly important because metabolic and mental health frequently overlap—and some psychiatric medications can themselves affect weight, glucose regulation, and lipid metabolism. Treating the mind while ignoring the metabolic health of the body can therefore leave an important part of the picture unaddressed.
Estrogen Helps Support Neuroplasticity
Estrogen also influences the physical and functional connections between neurons.
It affects synaptic plasticity—the brain's ability to strengthen, weaken, create, and reorganize connections in response to experience. The hippocampus, a region deeply involved in learning and memory, is particularly responsive to estrogen signaling (Brinton et al., 2015).
Changes in estrogen don't mean that neurons suddenly stop forming connections after menopause. The brain remains capable of learning and adaptation throughout life. But hormonal changes may influence the biological environment in which that plasticity occurs. This is one possible contributor to the cognitive changes some women notice during perimenopause, including difficulty retrieving words, maintaining attention, or remembering information as easily as they once did (Weber et al., 2014).
Importantly, brain fog during perimenopause does not mean that someone is developing dementia. Cognitive complaints are relatively common during the menopausal transition, and experiencing them should not automatically be interpreted as evidence of neurodegenerative disease.
What Does Any of This Have to Do With Alzheimer's Disease?
This is where the conversation requires particular care.
Women make up a substantial proportion of people living with Alzheimer's disease. Some of this difference is explained by longevity—women, on average, live longer than men—but researchers continue to investigate whether biological sex and hormonal factors also contribute (Rahman et al., 2019).
Estrogen interacts with several biological processes implicated in Alzheimer's disease, including glucose metabolism, mitochondrial function, inflammation, cerebral blood flow, synaptic health, and pathways involving amyloid and tau proteins (Brinton et al., 2015; Rahman et al., 2019).
Neuroimaging research has also identified menopause-associated changes in brain metabolism and Alzheimer's-related biomarkers, although the long-term meaning of these findings continues to be investigated (Mosconi et al., 2021). Researchers have therefore become increasingly interested in whether menopause represents a period of neurological vulnerability, adaptation—or both—that may influence cognitive aging later in life.
But this does not mean that menopause causes Alzheimer's disease. Nor does experiencing brain fog during perimenopause mean that dementia is beginning. Alzheimer's disease and other dementias develop through complicated interactions among aging, genetics, cardiovascular health, metabolic health, immune function, lifestyle, and numerous other factors.
Estrogen appears to be one part of a much larger story.
If Estrogen Is Protective, Should Everyone Take Hormone Therapy?
No.
This is an important distinction. Menopausal hormone therapy can be highly effective for vasomotor symptoms and other menopausal concerns in appropriately selected patients. However, major menopause guidance does not recommend prescribing hormone therapy solely for the prevention of dementia (The North American Menopause Society, 2022).
One reason this subject is complicated is that the effects of estrogen may depend partly on when it is given. Researchers have proposed what is sometimes called the "timing hypothesis" or "critical-window hypothesis." According to this idea, hormone therapy initiated around the menopausal transition may have different neurological and cardiovascular effects from estrogen initiated many years after menopause, when age-related vascular, metabolic, and neurological changes may already be present (Brinton et al., 2015).
This may help explain why studies of hormone therapy and cognitive outcomes have sometimes produced apparently conflicting results. The type of hormone, dose, route of administration, age at initiation, time since menopause, whether a progestogen is also required, and an individual's cardiovascular and medical risk factors may all matter.
Hormone therapy therefore isn't a one-size-fits-all intervention. Decisions about it should be individualized with a clinician knowledgeable about menopause care.
Midlife May Be an Important Window for Brain Health
Perhaps the most useful message from this research isn't that women should fear menopause. It's that brain health doesn't begin at age 70.
Many of the conditions associated with cognitive decline develop over decades. Hypertension, diabetes, poor sleep, physical inactivity, smoking, cardiovascular disease, depression, social isolation, and other potentially modifiable factors can influence long-term cognitive health.
Midlife therefore provides an important opportunity to identify and address risks.
That might mean:
Treating high blood pressure rather than ignoring it
Identifying insulin resistance and diabetes
Prioritizing consistent, restorative sleep
Engaging in regular aerobic physical activity
Maintaining muscle through resistance training
Eating a nutrient-dense dietary pattern
Avoiding smoking
Limiting excessive alcohol use
Treating significant depression and anxiety
Maintaining social relationships and cognitive engagement
Discussing significant menopausal symptoms with a knowledgeable healthcare professional
For some women, that conversation may include whether menopausal hormone therapy is appropriate. None of these interventions can guarantee that someone will never develop dementia. They are instead part of caring for the brain as an organ throughout the lifespan.
Mental Health Is Physical Health
Psychiatry has historically separated the "mind" from the rest of the body more than biology actually does. The brain doesn't exist in isolation. It communicates continuously with the endocrine system, immune system, gastrointestinal system, cardiovascular system, and the rest of the body. Hormones influence neurotransmitters. Sleep influences inflammation. Metabolic health influences vascular health. Exercise affects neuroplasticity. Chronic stress affects immune and endocrine function.
Perimenopause makes these connections particularly visible. A woman experiencing anxiety, depression, insomnia, or cognitive changes during midlife may need psychiatric treatment. She may also benefit from considering sleep, hormonal changes, metabolic health, nutrition, physical activity, medications, and other medical contributors.
These aren't competing explanations. They are different pieces of the same person.
Looking Beyond Symptoms
Menopause is a normal biological transition, not a disease. But "normal" doesn't mean biologically insignificant. The decline in ovarian hormones represents a substantial physiological transition affecting systems throughout the body—including the brain.
Understanding those changes gives us an opportunity to approach women's mental health differently: not simply by asking how we can suppress a symptom, but by asking what factors may be contributing to it and how we can support health more broadly. It also shifts the conversation about cognitive health earlier. We don't need to wait until someone is elderly to start caring about the health of her brain.
The cardiovascular, metabolic, emotional, and physical health of midlife may help shape the biological environment in which the brain ages. That is one of the central ideas behind a whole-person approach to mental health: What supports the body often supports the brain—and caring for the brain means caring for both.
References
Brinton, R. D., Yao, J., Yin, F., Mack, W. J., & Cadenas, E. (2015). Perimenopause as a neurological transition state. Nature Reviews Endocrinology, 11(7), 393–405. https://doi.org/10.1038/nrendo.2015.82
Maki, P. M., Kornstein, S. G., Joffe, H., Bromberger, J. T., Freeman, E. W., Athappilly, G., Bobo, W. V., Rubin, L. H., Koleva, H. K., Cohen, L. S., & Soares, C. N. (2018). Guidelines for the evaluation and treatment of perimenopausal depression: Summary and recommendations. Journal of Women's Health, 27(2), 117–134. https://doi.org/10.1089/jwh.2017.6459
Mosconi, L., Berti, V., Dyke, J., Schelbaum, E., Jett, S., Loughlin, L., Jang, G., Rahman, A., Hristov, H., Pahlajani, S., Andrews, R., Matthews, D., Etingin, O., Ganzer, C., de Leon, M., Vallabhajosula, S., Isaacson, R. S., & Brinton, R. D. (2021). Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Scientific Reports, 11, 10867. https://doi.org/10.1038/s41598-021-90084-y
Rahman, A., Jackson, H., Hristov, H., Isaacson, R. S., Saif, N., Shetty, T., Etingin, O., Henchcliffe, C., Brinton, R. D., & Mosconi, L. (2019). Sex and gender driven modifiers of Alzheimer's: The role for estrogenic control across age, race, medical, and lifestyle risks. Frontiers in Aging Neuroscience, 11, 315. https://doi.org/10.3389/fnagi.2019.00315
The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028
Weber, M. T., Maki, P. M., & McDermott, M. P. (2014). Cognition and mood in perimenopause: A systematic review and meta-analysis. Journal of Steroid Biochemistry and Molecular Biology, 142, 90–98. https://doi.org/10.1016/j.jsbmb.2013.06.001
This article is intended for educational purposes only and is not a substitute for individualized medical or psychiatric care. Decisions about menopausal hormone therapy, psychiatric treatment, or other medical interventions should be made with an appropriate healthcare professional based on individual symptoms, history, and risk factors.
